Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Red squares indicate positive associations; blue squares indicate negative associations. *P < 0.05; ** P < 0.01Alteration of Metabolites in AD subjects compared with cognitively normal controlsCompoundMetabolitePredicted molecular pathways or biological functionsaVIPFC(AD/NC)PLipids and lipid-like molecules Androstane steroids19-Oxoandrost-4-ene-3,17-dioneSteroid hormone biosynthesis2.40.730.023 Fatty acids5-Butyl-3,4-dimethyl-2-furanundecanoic acidAntixoxidants and radical scavengers2.10.800.034 Steroidal glycosidesTrigofoenoside FA compound isolated from fenugreek seeds1.51.070.011 Triterpenoids22-Angeloylbarringtogenol CA constituent of C. sinensis3.31.220.042 DiterpenoidsSagittariol: 2.60.870.042 Vitamin D derivatives1α,25-dihydroxy-3α-methyl-3-deoxyvitamin D3: 2.70.870.031: PG(16:0/0:0)[U]: 1.30.950.019Organic acids and derivatives Amino acidsN-Docosahexaenoyl GABAN-Acyl amino acid metabolism2.30.810.001 Hydroxy acids12-Hydroxydodecanoic acidSubstrate of glutathione-dependent formaldehyde dehydrogenase1.60.850.047 Amino acidsHypoglycin BNatural toxins1.40.860.037Benzenoids Methoxyphenols(4E)-12-hydroxy-1-(4-hydroxy-3-methoxyphenyl)dodec-4-en-3-oneA predicted metabolite generated by BioTransformer2.10.670.020 Benzenediols5-(3′,5′-Dihydroxyphenyl)-γ-valerolactoneA tea polyphenol metabolite detected in biological fluids2.30.730.041Organic nitrogen compounds AminesN,N-DimethylsphingosineRegulation of sphingolipid-mediated functions3.91.350.032Organoheterocyclic compounds Benzopyrans(5α,8β,9β)-5,9-Epoxy-3,6-megastigmadien-8-ol: 1.81.230.045Piperidine Piperidine1-ACETYLPIPERIDINEPiperidine metabolism1.90.800.041AD Alzheimer’s disease, NC cognitively normal control, VIP variable importance in the projection, FC fold changea Information referencing KEGG pathway database and HDBM database

Source: Fecal Metabolome between AD and NC participants. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

The results showed that the AD participants or NC participants were not clustered based on sex (Additional file : Fig.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Disturbed microbial ecology in Alzheimer’s disease: evidence from the gut microbiota and fecal metabolome

Study design awaiting verification · BMC Microbiology · 2021

Original publication title

Disturbed microbial ecology in Alzheimer’s disease: evidence from the gut microbiota and fecal metabolome

Jianxiong Xi; Ding Ding; Huiwei Zhu; Ruru Wang; Feng Su; Wanqing Wu; Zhenxu Xiao; Xiaoniu Liang; Qianhua Zhao; Zhen Hong; Hua Fu; Qianyi Xiao

© The Author(s) 2021

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

These findings demonstrate that gut microbial alterations and related metabolic output changes may be associated with pathogenesis of AD, and suggest that fecal markers might be used as a non-invasive examination to assist screening and diagnosis of AD.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Gut microbiota (GMB) alteration has been reported to influence the Alzheimer’s disease (AD) pathogenesis through immune, endocrine, and metabolic pathways. This study aims to investigate metabolic output of the dysbiosis of GMB in AD pathogenesis. In this study, the fecal microbiota and metabolome from 21 AD participants and 44 cognitively normal control participants were measured. Untargeted GMB taxa was analyzed through 16S ribosomal RNA gene profiling based on next-generation sequencing and fecal metabolites were quantified by using ultrahigh performance liquid chromatography-mass spectrometry (UPLC-MS).

Source: Background

Abstract: Results

Our analysis revealed that AD was characterized by 15 altered gut bacterial genera, of which 46.7% (7/15 general) was significantly associated with a series of metabolite markers. The predicted metabolic profile of altered gut microbial composition included steroid hormone biosynthesis, N-Acyl amino acid metabolism and piperidine metabolism. Moreover, a combination of 2 gut bacterial genera (Faecalibacterium and Pseudomonas) and 4 metabolites (N-Docosahexaenoyl GABA, 19-Oxoandrost-4-ene-3,17-dione, Trigofoenoside F and 22-Angeloylbarringtogenol C) was able to discriminate AD from NC with AUC of 0.955 in these 65 subjects.

Source: Results

Abstract: Conclusions

These findings demonstrate that gut microbial alterations and related metabolic output changes may be associated with pathogenesis of AD, and suggest that fecal markers might be used as a non-invasive examination to assist screening and diagnosis of AD.

Source: Conclusions
Authors’ abstract

Background

Gut microbiota (GMB) alteration has been reported to influence the Alzheimer’s disease (AD) pathogenesis through immune, endocrine, and metabolic pathways. This study aims to investigate metabolic output of the dysbiosis of GMB in AD pathogenesis. In this study, the fecal microbiota and metabolome from 21 AD participants and 44 cognitively normal control participants were measured. Untargeted GMB taxa was analyzed through 16S ribosomal RNA gene profiling based on next-generation sequencing and fecal metabolites were quantified by using ultrahigh performance liquid chromatography-mass spectrometry (UPLC-MS).

Results

Our analysis revealed that AD was characterized by 15 altered gut bacterial genera, of which 46.7% (7/15 general) was significantly associated with a series of metabolite markers. The predicted metabolic profile of altered gut microbial composition included steroid hormone biosynthesis, N-Acyl amino acid metabolism and piperidine metabolism. Moreover, a combination of 2 gut bacterial genera (Faecalibacterium and Pseudomonas) and 4 metabolites (N-Docosahexaenoyl GABA, 19-Oxoandrost-4-ene-3,17-dione, Trigofoenoside F and 22-Angeloylbarringtogenol C) was able to discriminate AD from NC with AUC of 0.955 in these 65 subjects.

Conclusions

These findings demonstrate that gut microbial alterations and related metabolic output changes may be associated with pathogenesis of AD, and suggest that fecal markers might be used as a non-invasive examination to assist screening and diagnosis of AD.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12866-021-02286-z.

Publication and source details

Original title: Disturbed microbial ecology in Alzheimer’s disease: evidence from the gut microbiota and fecal metabolome

Jianxiong Xi; Ding Ding; Huiwei Zhu; Ruru Wang; Feng Su; Wanqing Wu; Zhenxu Xiao; Xiaoniu Liang; Qianhua Zhao; Zhen Hong; Hua Fu; Qianyi Xiao

BMC Microbiology · 2021

© The Author(s) 2021https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.Shanghai Municipal Committee for Health and Family PlanningGWV-10.1-XK14Xiao Qianyi Scientific Research Starting Foundation from Fudan universityNational Chronic Disease Project2016YFC1306402Ding Ding Scientific Research Plan Project of Shanghai Science and Technology Committee1741195070117411950106Ding Ding Shanghai Municipal Science and Technology Major Project2018SHZDZX01Ding Ding

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T11:57:21.330526+00:00

DOI: 10.1186/s12866-021-02286-z · PMC8361629